PMC9880153_01
The genome coverage map of Leishmania donovani detected by mNGS in case 1. The genome coverage of Leishmania donovani in the peripheral blood of case 1 is 2.7%.
fmed-09-1044043-g0001.jpg
PMC9880153_01_fmed-09-1044043-g0001.jpg
F1
On January 24, 2021, peripheral blood mNGS was performed, and 11,552 reads of Leishmania genus-specific sequence were detected in microbial cell-free deoxyribonucleic acid (mcfDNA), and 7,509 reads were detected in microbial cell-free ribonucleic acid (mcfRNA) (Table 3), with a genome coverage of 2.7% (Figure 1). Figure 1). Finally, the patient was diagnosed with visceral leishmaniasis, sepsis, moderate anemia, rash, leukopenia, thrombocytopenia, grade 2 hypertension, and type 2 diabetes mellitus.
PMC9880153_02
The genome coverage map of Leishmania donovani detected by mNGS in case 2. The genome coverage of Leishmania donovani in the peripheral blood of case 2 is 0.2%.
fmed-09-1044043-g0002.jpg
PMC9880153_02_fmed-09-1044043-g0002.jpg
F2
On February 9, 2021, peripheral blood mNGS was performed, and 606 reads of Leishmania genus-specific sequence and 15 reads of L. donovani-specific sequence were detected in mcfDNA, accounting for 0.2% of genome coverage (Figure 2). On February 10, 2021, the bone marrow aspiration smear was re-examined, and ten suspected Leishmania were seen (Supplementary Figure 2).